国产精品99一区二区三_免费中文日韩_国产在线精品一区二区_日本成人手机在线

Adjusting therapeutic steps a promising strategy for treating lung cancer: study

Source: Xinhua| 2018-04-16 23:39:15|Editor: Mu Xuequan
Video PlayerClose

WASHINGTON, April 16 (Xinhua) -- A study has shown that a new, innovative approach to lung cancer treatment in which immunotherapy is administered prior to surgery is yielding encouraging outcomes in 45 percent of non-small cell lung cancer patients treated.

In a study published on Monday in the New England Journal of Medicine, Scientists at Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Memorial Sloan Kettering Cancer Center administered two doses of the anti-PD1 immunotherapy nivolumab for several weeks prior to surgery.

The therapy turned out to be not only safe but 45 percent of the patients in the initial trial responded so well that there was little evidence of the cancer remaining upon follow-up.

According to the researchers, the patients' immune systems also likely destroyed straggler tumor cells still circulating in the blood system, which can later take hold and lead to recurrence and metastasis.

"The team is using T cells, activated by immunotherapy prior to surgery, to continue to circulate through the patient's body, after surgery. These T cells can intervene, stopping errant tumor cells from forming new metastases, preventing recurrence," said Sung Poblete, CEO of Stand Up To Cancer, a foundation that funded the research.

Previously, chemotherapy or chemoradiotherapy is given to lung cancer patients to shrink a large, non-metastasized tumor while immunotherapeutic agents have been administered after surgery with limited results.

However, the researchers hypothesized that leaving the tumor in place during initial treatment with immunotherapy would turn it into an "auto-vaccine."

The "auto-vaccine" might result in the activation of tumor-specific T cells that would then circulate through the body and find distant sites of micrometastases, thereby preventing relapse post-surgery which can happen to at least one-half of lung cancer patients who undergo surgery.

After a median follow-up of 12 months, three-quarters of the patients who underwent surgical resection were alive and recurrence-free. Recurrence-free survival at 18 months was 73 percent.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011105091371156371
主站蜘蛛池模板: 新密市| 奇台县| 达孜县| 新宾| 莱州市| 永定县| 平乐县| 赤水市| 盱眙县| 金平| 淮南市| 梓潼县| 镇赉县| 巴塘县| 禹州市| 马尔康县| 凉城县| 莒南县| 敦煌市| 嫩江县| 枣庄市| 剑阁县| 台前县| 绩溪县| 松滋市| 衡阳市| 昭通市| 建水县| 西充县| 沁源县| 兴和县| 陆川县| 封开县| 青冈县| 镇原县| 灌南县| 普洱| 兴山县| 丹棱县| 民勤县| 正阳县|